In this week's podcast, Drs. Artie Kavanaugh and Jack Cush present highlights from the virtual EULAR2020 meeting held June 3-6, 2020. Featured reports include the SELECT-CHOICE study, the EXCEED trial, Avacopan in AAV, BeST mortality outcomes, BLISS-LN study, biosimilars and tofa in systemic sclerosis.
All News
Article
Article
These were my top abstracts from Thursday, 4th of June at EULAR 2020:
Article
These were my top abstracts from Thursday, 4th of June at EULAR 2020:
Article
For a disease that has been recognized since the days of Hippocrates, we are finally making some progress towards understanding systemic lupus erythematosus (SLE) and how to tame the wolf. Listed below are the top 5 studies and their summaries presented at the recent EULAR e-Congress confer
Article
Flares in ANCA-associated vasculitis are difficult to predict, but serum calprotectin may help predict relapse and renal failure, according to data presented at the EULAR 2020 virtual meeting this week.
Article
Here is my top-five from day one at EULAR:
#EULAR2020 #op0050 RCT ph4 results: in inadequately controlled PsA addition of ADA results in better outcomes in terms MDA, ACR20, PASI75, HAQ-DI&LEI as opposed to MTX dose escalation @RheumNow https://t.co/iMgCkRawCl
#EULAR2020 #LB0001 SELECT-PsA-1 Upadacitinib vs PBO vs ADA: UPA 15/30 mg non-inferior &UPA 30 superior to ADA for ACR20. At wk12 ACR 20 70.6% UPA15, 78.5% UPA30 vs 36.2%PBO & 65%ADA. Better ACR50/70 &MDA va PBO. No new safety signals. @RheumNow https://t.co/QZkMdoqXEC
#EULAR2020 #op0028 12 wk ph3 RELIEF study: Apremilast effectively relieves OU pain and OU number after 12 wks of 30 mg bid Rx. Great proportion of APR PTs achieved >10 mm &>30 mm improvement in OU pain @RheumNow https://t.co/p71sz9XL0e
David Liew
Tweet
Lots of talk about best bDMARDs in RA-ILD, but what about in RA-assoc bronchiectasis?
@Yuz6Yusof found rituximab had better 'lung survival' vs TNFi (similar baseline stats)
Something to consider in these difficult-to-treat pts?
@LeedsBRC Newcastle THU0143 #EULAR2020 @RheumNow https://t.co/XpffkDNqhU
David Liew
Tweet
For patients on bDMARDs having surgery, we worry about post-op delayed wound healing.
In this Japanese cohort, TCZ use was a risk factor.
Unclear if meds withheld, but given IL-6 upreg in wound healing, it's plausible TCZ might have worse outcomes??
SAT0047 #EULAR2020 @RheumNow https://t.co/HVIKPplwiA
Janet Pope
Tweet
Hand OA Rx strikes out. HCQ Rx neg and colchicine Trial negative. I wouldn’t put hand OA as same category of no Rx as for SSc and Sjogrens but agree though nuts to crack @eular_org @CRASCRRheum @earlyarthritis #EULAR2020 https://t.co/QRe3UpKpbz
Dr Philip Robinson
Tweet
Awesome colchicine data from @CatherineL_Hill @samwhittle and others: Colchicine is not effective for reducing osteoarthritic hand pain compared to placebo: a randomised, placebo-controlled trial (COLAH) Abstract FRI0399 #EULAR2020 @RheumNow https://t.co/NVw9fo55dc https://t.co/LfHZVQTwIf
Mohammad A. Ursani MD, RhMSUS
Tweet
#tacrolimus #prograf is non inferior to #MMF #cellcept in #lupus #nephritis induction. We’ve been doing it for years but great to see some solid RCT data behind this. #rheumatology #SLE #autoimmune https://t.co/CblD4GaXCp
#EULAR2020 Dr. V Ritschl:EULAR Task Force on Patient Adherance: 30-80% of pts do not adhere to Rx. resulting in ⬆️dz severity, pain, fatigue, depression, decreased in function, physical activity. HCPs should discuss adherance reg. & explore factors affecting adherance. @RheumNow
#EULAR2020 Updated RA Mgmt Recc
Main points:
1. MTX 1st line (if contraind, then SSZ/LEF; NOT HCQ)
2. Add bDMARD/JAKi if 1st csDMARD doesn't work + poor Px
3. Use IL-6i or JAKi for pts who can only take monoRx and failed csDMARD
@RheumNow
https://t.co/AIXz2dEOrX
Christos Koutsianas
Tweet
Do not be tempted to stop MTX or other DMARDs perioperatively! They probably help rather than harm #EULAR2020 https://t.co/jb4ZuZlqSu


